7月29日周二，基因诊断公司GeneDx Holdings（股票代码：WGS）发布了截至6月30日的2025年第二季度财报，业绩大幅超出市场预期，导致该公司股价在盘前交易中飙升29.08%。
财报显示，GeneDx Holdings第二季度调整后每股收益达到50美分，远超分析师平均预期的10美分，也大幅高于去年同期的亏损10美分。公司营收同比增长45.6%，达到1.0269亿美元，同样超过了分析师预期的8545万美元。值得注意的是，公司本季度实现净利润1081万美元，每股收益36美分，标志着公司成功扭亏为盈。
尽管GeneDx Holdings的股价在本季度下跌了8.0%，但今年迄今为止仍上涨了10.5%。分析师普遍看好该公司前景，目前对公司股票的平均评级为"买入"，12个月目标价中位数为110.00美元，较上一交易日收盘价84.91美元高出约22.8%。这份亮眼的财报无疑将进一步增强投资者对GeneDx Holdings未来发展的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.